Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease
Gut and Liver · 2026
DOI: 10.5009/gnl250188 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Gut and Liver, 2026. Verfasst von Yu Kyung Jun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. Hauptthemen laut MEDLINE: Gastrointestinal Agents, Antibodies, Monoclonal, Humanized, Inflammatory Bowel Diseases, Drug Substitution. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
- Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
- Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
ORCID-Profile: Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Sung Wook Hwang, Hyuk Yoon
Zitieren
APA
Jun, Y. K., Choi, Y., Shin, C. M., Park, Y. S., Kim, N., Lee, D. H., Hwang, S. W., & Yoon, H. (2026). Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease. Gut and Liver. https://doi.org/10.5009/gnl250188
Vancouver
Jun YK, Choi Y, Shin CM, Park YS, Kim N, Lee DH, et al. Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease. Gut and Liver. 2026. doi:10.5009/gnl250188
BibTeX
@article{Jun2026,
author = {Jun, Yu Kyung and Choi, Yonghoon and Shin, Cheol Min and Park, Young Soo and Kim, Nayoung and Lee, Dong Ho and Hwang, Sung Wook and Yoon, Hyuk},
title = {Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease},
journal = {Gut and Liver},
year = {2026},
doi = {10.5009/gnl250188}
}
EUVIMED